CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice

Human Genetics
Cong HuaiDa-Ru Lu

Abstract

Hemophilia B (HB) is an X-linked disorder caused by defects of F9 encoded coagulation factor IX, which is an ideal model for gene therapy. Most existing HB gene therapies are based on viral mediated gene supplementation, which could increase immunoreaction. In this study, CRISPR/Cas9 system was used for gene correction in an F9 mutant HB mouse model in both adult mice (in vivo) and in germline cells (ex vivo). In vivo, naked Cas9-sgRNA plasmid and donor DNA were delivered to HB mice livers to recover the mutation via hydrodynamic tail vein (HTV) injection. 62.5% of the HTV-treated mice showed a detectable gene correction (>1%) in the F9 alleles of hepatocytes, which was sufficient to remit the coagulation deficiency. Ex vivo, three different forms of Cas9 were microinjected into germline cells of HB mice to investigate their efficiency and safety in gene correction. Cas9 protein showed higher gene recovery rates, less embryo toxicity, and lower mosaic repair percentage, making it more suitable for germline gene therapy. Our study strongly supports that CRISPR/Cas9-mediated genome editing is feasible in gene therapy of genetic disorders.

References

Sep 1, 1991·Baillière's Clinical Obstetrics and Gynaecology·R V Lebo, M S Golbus
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·L WangI M Verma
Apr 3, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J YangY Liu
Jul 11, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haiyan JiangValder R Arruda
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Jan 5, 2013·Science·Le CongFeng Zhang
Feb 7, 2013·ELife·Martin JinekJennifer Doudna
Oct 3, 2013·Blood·Xavier M AnguelaKatherine A High
Nov 21, 2013·Genome Research·Young Hoon SungJin-Soo Kim
Nov 26, 2013·The International Journal of Biochemistry & Cell Biology·Jiankui ZhouXingxu Huang
Dec 10, 2013·Cell Stem Cell·Yuxuan WuJinsong Li
Jan 22, 2014·Nature Communications·Jong Min KimJin-Soo Kim
Apr 1, 2014·Nature Biotechnology·Hao YinDaniel G Anderson
Nov 20, 2014·The New England Journal of Medicine·Amit C NathwaniAndrew M Davidoff
Nov 8, 2016·Nature·Daniel P DeverMatthew H Porteus

❮ Previous
Next ❯

Citations

Feb 8, 2018·European Journal of Immunology·Katharina HochheiserMarco J Herold
Mar 1, 2018·Frontiers in Pediatrics·Elizabeth ForsythePhilip L Beales
Jan 26, 2018·Human Gene Therapy·Xionghao LiuDesheng Liang
Jun 20, 2019·Expert Review of Respiratory Medicine·Kamran M MiahDeborah R Gill
Aug 1, 2019·Human Gene Therapy·Hiu Man Grisch-ChanBeat Thöny
Jun 28, 2019·Clinical Pharmacology and Therapeutics·Cong HuaiShengying Qin
Nov 19, 2019·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Tian Liu, Zhigang Yang
Jul 16, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Xueqing DouRenchi Yang
Oct 1, 2020·PloS One·Michael PöhlerVanessa Sandfort
Jul 22, 2018·Frontiers in Genetics·Bhaskar RoyKarsten Kristiansen
Jun 13, 2020·Gene Therapy·Dawei WangYujia Cai
May 26, 2018·Biotechnology Journal·Elizabeth O'DaySang Yup Lee
Jun 12, 2020·Molecular Frontiers Journal·Cary O Harding
Jun 27, 2019·International Journal of Molecular Sciences·Dario Balestra, Alessio Branchini
Dec 18, 2019·Genome Biology·Jian-Ping ZhangXiao-Bing Zhang
Dec 22, 2017·Journal of Cellular Biochemistry·Rajagopal N Aravalli, Clifford J Steer
Mar 25, 2019·Bone Marrow Transplantation·Alberto Daniel-MorenoMarkus Mezger
Oct 3, 2020·Computational and Structural Biotechnology Journal·Yuanyuan Xu, Zhanjun Li
Feb 1, 2020·Progress in Retinal and Eye Research·Nadia Sukusu NielsenJan J Enghild
Aug 11, 2020·Molecular Therapy. Methods & Clinical Development·Martijn P T ErnstW W M Pim Pijnappel
Jun 10, 2018·Clinics and Research in Hepatology and Gastroenterology·Robin LoeschSabine Colnot
Jul 3, 2021·Cells·Lola KonialiMarina Kleanthous
Sep 13, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gregory A Newby, David R Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transfection
ELISA
gene knockout
biopsies

Software Mentioned

/ BLAT
BLAST
Ensembl
RGEN

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.